Retinoic Acid 4-Hydroxylase (CYP26B1)

A cytochrome P450 enzyme that resides in the ENDOPLASMIC RETICULUM. It catalyzes the conversion of trans-RETINOIC ACID to 4-hydroxyretinoic acid.

Also Known As:

CYP26B1; CYP26A1; CYP26A1 Enzyme; CYP450 4-Hydroxylase; Cytochrome P-450 26B1; Cytochrome P-450 CYP26B1; Cytochrome P450 26A1 Enzyme; Cytochrome P450 4-Hydroxylase; P450RAI; RA-4-Hydroxylase; Retinoic Acid-Metabolizing Enzyme, CYP26B1; CYP26B1, Cytochrome P-450; Cytochrome P 450 CYP26B1; Cytochrome P450 4 Hydroxylase; Enzyme, CYP26A1; RA 4 Hydroxylase; Retinoic Acid 4 Hydroxylase; Retinoic Acid Metabolizing Enzyme, CYP26B1

Networked: 108 relevant articles (4 outcomes, 9 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Osanai, Makoto: 7 articles (06/2018 - 06/2011)
2.	Petkovich, Martin: 6 articles (07/2015 - 05/2002)
3.	Chen, Ping-Ho: 5 articles (11/2020 - 07/2011)
4.	Lee, Gang-Hong: 5 articles (03/2016 - 06/2011)
5.	Lee, Ka-Wo: 3 articles (11/2020 - 07/2011)
6.	Robertson, Stephen P: 3 articles (12/2018 - 11/2011)
7.	Armstrong, Jane L: 3 articles (10/2011 - 09/2008)
8.	Brancale, Andrea: 3 articles (10/2011 - 09/2008)
9.	Redfern, Christopher P F: 3 articles (10/2011 - 09/2008)
10.	Simons, Claire: 3 articles (10/2011 - 09/2008)

Related Diseases

1.	Acute Promyelocytic Leukemia 10/01/2005 - "Regulation of a highly specific retinoic acid-4-hydroxylase (CYP26A1) enzyme and all-trans-retinoic acid metabolism in human intestinal, liver, endothelial, and acute promyelocytic leukemia cells." 10/01/2005 - "The recently identified retinoic acid (RA)-metabolizing cytochrome P450RAI-1 (CYP26A1) has been implicated in accelerated metabolism and rapid clearance of all-trans-retinoic acid (ATRA) during prolonged oral administration in patients with acute promyelocytic leukemia (APL), leading to a progressive decline in plasma drug levels. "
2.	Neuralgia (Stump Neuralgia) 08/28/2023 - "CYP26A1 may be a potential therapeutic target for the treatment of neuropathic pain." 08/28/2023 - "Inhibition of CYP26A1 by siRNA or inhibition of CYP26A1-mediated at-RA catabolism by talarozole relieved the SNL-induced mechanical allodynia during the maintenance phase of neuropathic pain. "
3.	Darier Disease (Darier's Disease) 01/01/2021 - "Substrate-based inhibitor DX314 has enhanced selectivity for RA-metabolizing enzyme CYP26B1 and may offer an improved treatment option for keratinization disorders such as congenital ichthyosis and Darier disease. "
4.	Ichthyosis (Xeroderma) 01/01/2021 - "Substrate-based inhibitor DX314 has enhanced selectivity for RA-metabolizing enzyme CYP26B1 and may offer an improved treatment option for keratinization disorders such as congenital ichthyosis and Darier disease. "
5.	Hyperalgesia 08/28/2023 - "Inhibition of CYP26A1 by siRNA or inhibition of CYP26A1-mediated at-RA catabolism by talarozole relieved the SNL-induced mechanical allodynia during the maintenance phase of neuropathic pain. "

Related Drugs and Biologics

1.	Tretinoin (Retinoic Acid)
2.	Enzymes
3.	R 115866
4.	Messenger RNA (mRNA)
5.	Cytochromes
6.	Small Interfering RNA (siRNA)
7.	kakkon-to
8.	Retinoic Acid 4-Hydroxylase (CYP26B1)
9.	Peptides (Polypeptides)
10.	Cytochrome P450 Family 26

Related Therapies and Procedures

1.	Therapeutics
2.	Oral Administration
3.	Sutures (Suture)
4.	Immunotherapy